8-K 1 h64687e8vk.htm FORM 8-K - CURRENT REPORT e8vk
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Filed Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): October 29, 2008
Repros Therapeutics Inc.
(Exact name of registrant as specified in its charter)
         
Delaware
(State or other jurisdiction of
incorporation or organization) 		  001-15281
(Commission File Number) 		  76-0233274
(I.R.S. Employer Identification No.)
2408 Timberloch Place, Suite B-7
The Woodlands, Texas 77380
(Address of principal
executive offices
and zip code)
(281) 719-3400
(Registrant’s telephone
number, including area
code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 7.01.   Regulation FD Disclosure
     The information in this Current Report is being furnished pursuant to Item 7.01 of Form 8-K and, according to general instruction B.2. thereunder, the information in this Current Report shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933.
     Repros Therapeutics Inc. (the “Company”) announced today that the Company’s President and CEO, Joseph Podolski, will present a corporate overview on Monday, November 3, 2008, at 2:00 p.m. Eastern Time during the Oppenheimer 19th Annual Healthcare Conference. Mr. Podolski will also present on Tuesday, November 11, 2008, at 10:20 a.m. Eastern Time during the Rodman & Renshaw 10th Annual Healthcare Conference. And on December 2, 2008, at 8:00 a.m. Eastern Time, Mr. Podolski will present from the 20th Annual Piper Jaffray Healthcare Conference.
     To access each live presentation, log onto the Company’s website at http://www.reprosrx.com and click on the “Investors and Media” tab. Please connect to the website prior to the start of the relevant webcast to ensure adequate time to download any software that may be necessary. Each webcast recording will be archived and available on the Company’s website for 90 days following the relevant presentation.
     A copy of the Company’s press release is attached hereto as Exhibit 99.1. The press release is incorporated by reference herein and the foregoing description of the press release is qualified in its entirety by reference to the attached exhibit.
Item 9.01.   Financial Statements and Exhibits
     d. Exhibits
         
Exhibit    
Number   Description
       
 
  99.1    
Press Release dated October 29, 2008.

 

 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  Repros Therapeutics Inc.
 		  
Date: October 29, 2008.  By:   /s/ Louis Ploth, Jr.    
    Louis Ploth, Jr.   
    Vice President, Business Development and Chief Financial Officer   
 

 

 

EXHIBIT INDEX
         
Exhibit    
Number   Description
       
 
  99.1    
Press Release dated October 29, 2008.